Racial and ethnic disparities in asthma incidence and outcomes in the US are well documented.1 Less is known about disparities in inhaler use, the mainstay of asthma treatment. Prior studies published in the late 1990s reported underusage of inhaled corticosteroids (ICS) and other controller medications among Black and Hispanic patients compared with White patients2,3; however, less is known about current variation in use. Herein, updated national estimates of inhaler use among US adults with asthma are provided, examining how demographic, socioeconomic, clinical, and health care access factors may contribute to observed differences.
